CIA
AMED

Capital Impact Advisors’s Amedisys AMED Stock Holding History

Capital Impact Advisors’s Portfolio AMED Stock Details AMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-4,854
Closed -$444K – 112
2023
Q2 		$444K Buy
4,854
+339
+8% +$27.8K 0.49% 104
2023
Q1 		$332K Sell
4,515
-2,261
-33% -$196K 0.41% 115
2022
Q4 		$566K Buy
6,776
+386
+6% +$34.8K 0.55% 68
2022
Q3 		$563K Sell
6,390
-1,333
-17% -$159K 0.56% 64
2022
Q2 		$812K Sell
7,723
-783
-9% -$100K 0.75% 22
2022
Q1 		$1.47M Sell
8,506
-6,588
-44% -$984K 1.07% 9
2021
Q4 		$2.44M Buy
15,094
+5,676
+60% +$912K 1.69% 12
2021
Q3 		$1.4M Buy
+9,418
New +$1.96M 0.56% 79

Other funds holding AMED

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
WCMNY
Westchester Capital Management (New York) Valhalla, New York $2.21B AUM 26.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

Capital Impact Advisors's AMED Position: Q3 2023 in Review

Capital Impact Advisors sold out of Amedisys (AMED) in Q3 2023, closing a stake of 4,854 shares — an estimated $444K sold.

Capital Impact Advisors first reported a position in AMED in Q3 2021 and held it in 8 quarters. The position peaked at $2.44M in Q4 2021. 286 funds tracked by Wall St. Rank hold AMED as of Q3 2023.

  • Capital Impact Advisors reported no remaining Amedisys position as of Q3 2023 after selling out during the quarter.
  • Capital Impact Advisors sold 4,854 Amedisys shares in Q3 2023, an estimated $444K.
  • Capital Impact Advisors first reported a position in Amedisys in Q3 2021 and held it in 8 quarters.
  • Capital Impact Advisors's Amedisys position peaked at $2.44M in Q4 2021.
  • 286 funds tracked by Wall St. Rank held Amedisys as of Q3 2023.

Based on Capital Impact Advisors's 13F filing for Q3 2023, filed 15 Nov 2023.